

DAFTAR PUSTAKA




1. Badan Penelitian dan Pengembangan Kesehatan. Kementrian Kesehatan RI. Riset Kesehatan dasar (Riskesdas 2013). Jakarta ; 2013
2. Centers for Disease Control and Prevention. About High Blood Pressure [internet]. Atlanta : Division for Heart Disease and Stroke Prevention; [updated 2014 Jul 7; cited 2015 Jan 11] . Available from : <http://www.cdc.gov/bloodpressure/about.htm>
3. Yogiantoro M. Buku Ajar Ilmu Penyakit Dalam. 6th ed. Jakarta : InternaPublishing; 2014. Chapter 294, Pendekatan Klinis Hipertensi; p 2259-93
4. National Health Service. Complication of High Blood Pressure [internet]. 2014 Mar 7. [cited 2014 Des 24]. Available from : [http://www.nhs.uk/Conditions/Bloodpressure\(high\)/Pages/Complications.aspx](http://www.nhs.uk/Conditions/Bloodpressure(high)/Pages/Complications.aspx)
5. World Health Organization. Global Health Observatory (GHO) : Raised Blood Pressure [internet]. [cited 2015 Jan 11]. Available from : http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/
6. World Health Organization. Global Status Report On Noncommunicable Diseases 2010. 2011. p. 161
7. Kementrian Kesehatan RI. Buletin Jendela Data dan Informasi Kesehatan : Penyakit Tidak Menular. 2012
8. World Health Organization. Non Communicable Disease Country Profiles 2011. 2011. p. 207
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA et al. The Seventh Report of the Joint Nasional Committee, on Prevention, Detection, Evaluatin, and Treatment of High Blood Pressure. Hypertension. 2003;43:1206-52
10. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20

11. Weber Michael A, Schiffrin Ernesto L, White William B, Mann Samuel, Lindholm Lars H et al. Clinical Practice Guidelines for the Management of Hypertension in the Community : A Statement by the American Society of Hypertension and the International Society of Hypertension. *The Journal of Clinical Hypertension*. 2014 Jan ; 16(1): 14–26
12. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A Et al. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2013 Jul; 31(7):1281-357
13. Rilantono LI. Penyakit Kardiovaskular. Jakarta : Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2013
14. Oparil S, Zaman MA, Calhoun DA. Review : Pathogenesis of Hypertension. *Ann Intern Med*. 2003; 139: 761-776
15. Atlas SA. The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition. *JMCP* . 2007 Oct; 13(8) : S9-20
16. Cohuet G, Boudier HS. Mechanism of Target Organ Damage by Hypertension : Therapeutc Potential. *Pharmtera*; 2006; 111 : 81-98
17. Mensah GA, Croft JB, Giles WH. The Heart, Kidney, and Brain as Target Organs in Hypertension. *Curr Probl Cardiol*. 2003 Feb; 28(2):156-193
18. Maslim R. Buku Saku Diagnosis Gangguan Jiwa Rujukan Ringkas dari PPDGJ-III. Jakarta : PT Nuh Jaya;2001
19. Ruilope LM, Bakris GL. Renal Function and Target Organ Damage in Hypertension. *Eur Heart J*. 2011 Jul;32(13):1599-604
20. American Health Association. About Peripheral Artery Disease (PAD) [internet]. [updated 2014 Sep 15; cited 2015 Feb 9]. Available from : http://www.heart.org/HEARTORG/Conditions/More/PeripheralArteryDisease/About-Peripheral-Artery-Disease-PAD_UCM_301301_Article.jsp
21. Eva PR, Whitcher JP. Vaughan & Ashbury Oftalmologi Umum. Jakarta : Penerbit Buku Kedokteran EGC; 2007

22. Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor 328/MENKES/IX/2013 tentang Formularium Nasional;2013
23. Matsui D . Medication Adherence Issues in patients: Focus on Cost. 2013 March; 5 : 33-42
24. Katzung BG. Farmakologi Dasar & Klinik. Jakarta : Penerbit Buku Kedokteran ECG; 2007
25. Vasan RS, Larson MG, Leip EP, Evans JL, O'Donnell CJ, Kannel WB et al. Impact of High Normal Blood Pressure on the Risk of Cardiovascular Risk. N Engl J Med.2001. November 1; 345(18):1291-7
26. Ornstein SM, Nietert PJ, Dickerson LM. Hypertension management and control in primary care: a study of 20 practices in 14 states. Pharmacotherapy. 2004 Apr; 24(4) : 500-7
27. Rumanggit BI, Pojoh JA, Manampiring VN. Studi Deskriptif Pemberian Obat pada Pasien Hipertensi di PUSKESMAS Sario. JIF. 2012 ; 3(2)
28. American Heart Association. Statistical Fact Sheet : High Blood Pressure. 2013
29. Vuylsteke A, Vincent JL, Garanderie DPL, Anderson FA, Emery L, Wyman A et al. Characteristic, Practice Patterns and Outcomes in Patients with Acute Hypertension : European Registry for Studying the Treatment of Acute Hypertension (Euro-STAT). Critical Care. 2011; 15 : R271
30. Gudmundson LS, Johannsson M, Thorgeirsson G, Sigfusson N, Sigvaldason H, Wittman JC. Risk Profiles and Prognosis of Treated and Untreated Hypertensive Men and Women in a Population-based Longitudinal Study : The Reykjavik Study. J Hum Hypertens. 2004 Sep; 18 (9) : 615-22
31. Ekwunife OI, Ubaka CM. Drug Utilization Review of Antihypertensive Therapy among Patients with Compelling Indications in Two Hospitals in South-Eastern Nigeria. Journal Of Pharmacy and Pharmacological Research. 2011 Sept; 2(1) : pp. 25 – 28
32. Northern Illinois University College of Education. Factors That can Affect the Finders of a Study [internet]. [cited 2015 Jun 28]. Available at : http://www.cedu.niu.edu/~sorensen/502/procedure_notes.htm

33. Beg MA, Dutta S, Amit V, Kant R, Bawa S, Anjoom M. A Study on Drug Prescribing Pattern in Hypertensive Patients in a Tertiary Care Teaching Hospital at Dehradun, Uttarakhand. *Int J Med Sci Public Health*. 2014; 3(8): 922-926
34. US Department of Health and Human Service. How is Coronary Heart Disease Treated [internet]. [cited 2015 Jun 28]. Available at : www.nhlbi.nih.gov/health/health-topics/topics/cad/treatment
35. WebMD. Heart Disease Health Center : Angiotensin II Receptor Blockers (ARB) [internet]. [cited 2015 Jun 28]. Available from : www.Webmd.com/heart_disease/angiotensin-ii-receptor-blockers-arbs
36. Medical letters. Treatment Guidelines from the Medical Letter : Drugs for Hypertension [internet]. 2012 Jan. *The medical letter, inc.* 10 (113). Available at : www.medicalletter.org
37. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Roger S. Blumenthal RS et al. Treatment of Hypertension in Patients With Coronary Artery Disease : A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. *Hypertension*. 2015 May 12; 65 (18): 1998–2038
38. Dawalji S, Venkateshwarlu K, Thota S, Venisetty PK, Venisetty RK. Prescribing Pattern in Coronary Artery Disease: A Prospective Study. *IJPRR*. March 2014; 3(3):24-33

Lampiran 1. Ethical Clearance

	<p>KOMISI ETIK PENELITIAN KESEHATAN (KEPK) FAKULTAS KEDOKTERAN UNIVERSITAS DIPONEGORO DAN RSUP dr KARIADI SEMARANG Sekretariat : Kantor Dekanat FK Undip Lt.3 Jl. Dr. Soetomo 18. Semarang Telp/Fax. 024-8318350</p>	
<p>ETHICAL CLEARANCE No. 119/EC/FK-RSDK/2015</p>		
<p>Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Diponegoro RSUP. Dr. Kariadi Semarang, setelah membaca dan menelaah Usulan Penelitian dengan judul :</p>		
<p>POLA TERAPI ANTIHIPERTENSI PADA PASIEN RAWAT JALAN POLI JANTUNG RSUP. DR. KARIADI SEMARANG</p>		
Peneliti Utama	:	Ainurrizqi Intan Puspitasari
Pembimbing	:	1. dr. Ilham Uddin, Sp.JP, FIHA 2. dr. Pipin Ardianto, Sp.JP, FIHA
Penelitian	:	Dilaksanakan di Bagian Rekam Medik Poli Rawat Jalan Bagian Jantung dan Pembuluh Darah RSUP. Dr. Kariadi Semarang
<p>Seluju untuk dilaksanakan, dengan memperhatikan prinsip-prinsip yang dinyatakan dalam Deklarasi Helsinki 1975, yang diamended di Seoul 2008 dan Pedoman Nasional Etik Penelitian Kesehatan (PNEPK) Departemen Kesehatan RI 2011</p>		
<p>Penelitian ini adalah Rekam Medik, jadi tidak memerlukan Informed Consent Peneliti diwajibkan menyerahkan :</p>		
<ul style="list-style-type: none"> - Laporan kemajuan penelitian (<i>clinical trial</i>) - Laporan kejadian efek samping jika ada - Laporan ke KEPK jika penelitian sudah selesai & dilampiri Abstrak Penelitian 		
<p>Semarang, 20 MAR 2015</p>		
<p>Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Undip-RS. Dr. Kariadi Sekretaris</p>		
		
<p>Dr.dr.Selamat Budijitno,M.Si.Med.Sp.B,Sp.B(K),Onk,FICS NIP. 19710807 200812 1 001</p>		

Lampiran 2. Surat Ijin Penelitian

KEMENTERIAN KESEHATAN RI
DIREKTORAT JENDERAL BINA UPAYA KESEHATAN
RUMAH SAKIT UMUM PUSAT DOKTER KARIADI

Jl. Dr. Sutomo No. 16 Semarang, PO Box 1104

Telepon : (024) 8413993, 8413476, 8413764 Fax : (024) 8318617

Website : <http://www.rskariadi.co.id> email : humas_rskariadi@yahoo.co.id, rsdk@indosat.net.id



SURAT IZIN
MELAKSANAKAN PENELITIAN

DL.00.02 / I.III / 1309 / 2015

Yang bertanda tangan di bawah ini :

Nama : Dr. Darwito, SH, Sp.B, SpB(K), Onk
 N I P : 19600203 198803 1 003
 Jabatan : Direktur Umum & Operasional RSUP Dr. Kariadi

Memberikan ijin melakukan penelitian untuk :

Nama peneliti : Ainurrizqi Intan P
 Pembimbing : 1. dr Ilham Uddin, SpJP, FIHA
 2. dr Pipin Ardhianto, Sp.JP, FIHA
 Institusi peneliti : FK UNDIP
 Judul penelitian : Pola Terapi Antihiperterisi pada Pasien Rawat Jalan Poli Jantung
 RSUP dr Kariadi Semarang
 Lokasi penelitian : Instalasi Rekam Medis

Untuk melaksanakan kegiatan penelitian selama 2 bulan, terhitung mulai sejak diterbitkannya surat ijin penelitian ini.

Peneliti wajib melakukan :

1. Informed Consent dilampirkan pada rekam medis responden
2. Laporan monitoring evaluasi penelitian secara periodik
3. Laporan selesai penelitian dengan menyerahkan monitoring evaluasi penelitian
4. Menyerahkan laporan hasil akhir penelitian (1 berkas)

Semarang, 06 MAY 2015

An. Direktur Utama
 Direktur Umum & Operasional

Dr. Darwito, SH, Sp.B, SpB(K), Onk
 NIP . 19600203 198803 1 003

Lampiran 3. Data Output SPSS**Jenis kelamin**

	Frequency	Percent	Valid Percent	Cumulative Percent
Perempuan	59	34.5	34.5	34.5
Valid Laki - Laki	112	65.5	65.5	100.0
Total	171	100.0	100.0	

Descriptives

		Statistic	Std. Error	
usia pasien	Mean	62.04	.735	
	95% Confidence Interval for Mean	Lower Bound	60.58	
		Upper Bound	63.49	
	5% Trimmed Mean	62.15		
	Median	62.00		
	Variance	92.434		
	Std. Deviation	9.614		
	Minimum	31		
	Maximum	86		
	Range	55		
	Interquartile Range	11		
	Skewness	-.148	.186	
	Kurtosis	.186	.369	

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
usia pasien	.057	171	.200*	.993	171	.546

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

usia kategorik untuk frekuensi

	Frequency	Percent	Valid Percent	Cumulative Percent
2	68	39.8	39.8	39.8
Valid 3	103	60.2	60.2	100.0
Total	171	100.0	100.0	

Descriptives

		Statistic	Std. Error
TD sistol	Mean	131.19	1.214
	95% Confidence Interval for Mean	Lower Bound Upper Bound	128.79 133.58
	5% Trimmed Mean	130.48	
	Median	130.00	
	Variance	251.988	
	Std. Deviation	15.874	
	Minimum	100	
	Maximum	178	
	Range	78	
	Interquartile Range	20	
	Skewness	.549	.186
	Kurtosis	-.183	.369

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
TD sistol	.175	171	.000	.939	171	.000

a. Lilliefors Significance Correction

		Statistic	Std. Error
TD	Mean	81.43	.659

diastol	Lower Bound	80.13	
95% Confidence Interval for Mean	Upper Bound	82.73	
5% Trimmed Mean		81.23	
Median		80.00	
Variance		74.364	
Std. Deviation		8.623	
Minimum		60	
Maximum		118	
Range		58	
Interquartile Range		10	
Skewness		.547	.186
Kurtosis		2.388	.369

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
TD diastol	.273	171	.000	.851	171	.000

a. Lilliefors Significance Correction

terapi ace inhibitor

	Frequency	Percent	Valid Percent	Cumulative Percent
Tidak Mendapat	154	90.1	90.1	90.1
Valid Perindopril	6	3.5	3.5	93.6
Ramipril	10	5.8	5.8	99.4
Captopril	1	.6	.6	100.0
Total	171	100.0	100.0	

terapi ARB

	Frequency	Percent	Valid Percent	Cumulative Percent
Tidak mendapat	53	31.0	31.0	31.0
Valid Candesartan	58	33.9	33.9	64.9
Telmisartan	19	11.1	11.1	76.0
Valsartan	36	21.1	21.1	97.1
Irbesartan	5	2.9	2.9	100.0
Total	171	100.0	100.0	

terapi CCB

	Frequency	Percent	Valid Percent	Cumulative Percent
Tidak mendapat	110	64.3	64.3	64.3
Valid Amilodipin	32	18.7	18.7	83.0
Diltiazem	21	12.3	12.3	95.3
Nifedipin	8	4.7	4.7	100.0
Total	171	100.0	100.0	

terapi BB

	Frequency	Percent	Valid Percent	Cumulative Percent
tidak Mendapat	60	35.1	35.1	35.1
Valid Bisoprolol	97	56.7	56.7	91.8
Carvedilol	14	8.2	8.2	100.0
Total	171	100.0	100.0	

Furosemid

	Frequency	Percent	Valid Percent	Cumulative Percent
tidak mendapat	156	91.2	91.2	91.2
Valid Furosemid	15	8.8	8.8	100.0

Total	171	100.0	100.0
-------	-----	-------	-------

spironolact

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat spironolacton	131	76.6	76.6	76.6
Total	171	100.0	100.0	100.0

indapamide

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat indapamid	170	99.4	99.4	99.4
Total	171	100.0	100.0	100.0

HCT

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat HCT	164	95.9	95.9	95.9
Total	171	100.0	100.0	100.0

Clopidrogel

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat Clopidrogel	134	78.4	78.4	78.4
Total	171	100.0	100.0	100.0

Aspirin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat Aspirin	60	35.1	35.1	35.1
Total	111	64.9	64.9	100.0
	171	100.0	100.0	

Cilostazol

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat Cilostazol	170	99.4	99.4	99.4
Total	1	.6	.6	100.0
	171	100.0	100.0	

Warfarin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat Warfarin	152	88.9	88.9	88.9
Total	19	11.1	11.1	100.0
	171	100.0	100.0	

Simvastatin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat Simvastatin	89	52.0	52.0	52.0
Total	82	48.0	48.0	100.0
	171	100.0	100.0	

atrovastatin

	Frequency	Percent	Valid Percent	Cumulative Percent
--	-----------	---------	---------------	--------------------

Valid	tidak mendapat Atrovastatin	160	93.6	93.6	93.6
	Total	171	100.0	100.0	100.0

B1B6B12

	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	tidak mendapat B1B6B12	161	94.2	94.2	94.2
	Total	171	100.0	100.0	100.0

VitC

	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	tidak mendapat Vit. C	169	98.8	98.8	98.8
	Total	171	100.0	100.0	100.0

Bcom

	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	tidak mendapat B Comp	170	99.4	99.4	99.4
	Total	171	100.0	100.0	100.0

AsFolat

	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	tidak mendapat Asam Folat	164	95.9	95.9	95.9
	Total	171	100.0	100.0	100.0

CalsiumC

	Frequency	Percent	Valid Percent	Cumulative Percent
tidak mendapat	166	97.1	97.1	97.1
Valid Calsium Carbonat	5	2.9	2.9	100.0
Total	171	100.0	100.0	

Ferrous

	Frequency	Percent	Valid Percent	Cumulative Percent
tidak mendapat	170	99.4	99.4	99.4
Valid Ferrous	1	.6	.6	100.0
Total	171	100.0	100.0	

Allopurinol

	Frequency	Percent	Valid Percent	Cumulative Percent
tidak mendapat	146	85.4	85.4	85.4
Valid Allopurinol	25	14.6	14.6	100.0
Total	171	100.0	100.0	

Glimepirid

	Frequency	Percent	Valid Percent	Cumulative Percent
tidak mendapat	146	85.4	85.4	85.4
Valid Glimepirid	25	14.6	14.6	100.0
Total	171	100.0	100.0	

Glibenclamid

	Frequency	Percent	Valid Percent	Cumulative Percent

Valid	tidak mendapat	170	99.4	99.4	99.4
	Glibenclamid	1	.6	.6	100.0
	Total	171	100.0	100.0	

Metformin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	tidak mendapat	153	89.5	89.5
	Metformin	18	10.5	100.0
	Total	171	100.0	100.0

Gliclazide

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	tidak mendapat	165	96.5	96.5
	Gliclazide	6	3.5	100.0
	Total	171	100.0	100.0

Glikuidon

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	tidak mendapat	170	99.4	99.4
	Glikuidon	1	.6	100.0
	Total	171	100.0	100.0

Acarbose

	Frequenc y	Percent	Valid Percent	Cumulative Percent
Valid	tidak mendapat	164	95.9	95.9
	Acarbose	7	4.1	100.0
	Total	171	100.0	100.0

Insulin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat Insulin	170	99.4	99.4	99.4
Valid Insulin	1	.6	.6	100.0
Valid Total	171	100.0	100.0	

Proglitasone

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat Proglitasone	170	99.4	99.4	99.4
Valid Proglitasone	1	.6	.6	100.0
Valid Total	171	100.0	100.0	

Trinitrat

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat Gliseril Trinitrat	137	80.1	80.1	80.1
Valid Gliseril Trinitrat	34	19.9	19.9	100.0
Valid Total	171	100.0	100.0	

ISDN

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat ISDN	161	94.2	94.2	94.2
Valid ISDN	10	5.8	5.8	100.0
Valid Total	171	100.0	100.0	

digoxin

	Frequency	Percent	Valid Percent	Cumulative Percent

Valid	tidak mendapat	158	92.4	92.4	92.4
	digoxin	13	7.6	7.6	100.0
	Total	171	100.0	100.0	

ranitidine

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	tidak mendapat	169	98.8	98.8
	Ranitidine	2	1.2	100.0
	Total	171	100.0	100.0

lansoprazole

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	tidak mendapat	160	93.6	93.6
	lansoprazole	11	6.4	100.0
	Total	171	100.0	100.0

Domperidon

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	tidak mendapat	170	99.4	99.4
	Domperidon	1	.6	100.0
	Total	171	100.0	100.0

Betahistin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid	tidak mendapat	169	98.8	98.8
	Betahistin	2	1.2	100.0
	Total	171	100.0	100.0

asmef

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat Asam mefenamat	170	99.4	99.4	99.4
Total	171	100.0	100.0	100.0

piroxicam

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat piroxicam	170	99.4	99.4	99.4
Total	171	100.0	100.0	100.0

nadiclofenac

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat Na Diclofenac	170	99.4	99.4	99.4
Total	171	100.0	100.0	100.0

alprazolam

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat aprazolam	169	98.8	98.8	98.8
Total	171	100.0	100.0	100.0

Tiotropium

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat tiotropium	170	99.4	99.4	99.4
Total	171	100.0	100.0	100.0

Total	171	100.0	100.0
-------	-----	-------	-------

Seretide

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat seretide	169	98.8	98.8	98.8
Valid seretide	2	1.2	1.2	100.0
Valid Total	171	100.0	100.0	

Teofilin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat teofilin	168	98.2	98.2	98.2
Valid teofilin	3	1.8	1.8	100.0
Valid Total	171	100.0	100.0	

Symbicort

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat Symbicort	170	99.4	99.4	99.4
Valid Symbicort	1	.6	.6	100.0
Valid Total	171	100.0	100.0	

Harnal

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid tidak mendapat harnal	170	99.4	99.4	99.4
Valid harnal	1	.6	.6	100.0
Valid Total	171	100.0	100.0	

compelling indication

		Frequenc y	Percent	Valid Percent	Cumulative Percent
	tanpa compelling indication	1	.6	.6	.6
Valid	CHF	102	59.6	59.6	60.2
	IHD	68	39.8	39.8	100.0
	Total	171	100.0	100.0	

pembagian CHF

		Frequenc y	Percent	Valid Percent	Cumulative Percent
	CHF	73	42.7	71.6	71.6
	CHF+DM	24	14.0	23.5	95.1
Valid	CHF+CK D	5	2.9	4.9	100.0
	Total	102	59.6	100.0	
Missing	System	69	40.4		
Total		171	100.0		

pembagian IHD

		Frequenc y	Percent	Valid Percent	Cumulative Percent
	IHD	44	25.7	64.7	64.7
	IHD+DM	23	13.5	33.8	98.5
Valid	IHD+CK D	1	.6	1.5	100.0
	Total	68	39.8	100.0	
Missing	System	103	60.2		
Total		171	100.0		

terapi CHF

	Frekuensi	Percent	Valid Percent	Cumulative Percent
ARB	3	1.8	2.9	2.9
CCB	2	1.2	2.0	4.9
BB	7	4.1	6.9	11.8
Diuretik	1	.6	1.0	12.7
Aldosteron inhibitor	1	.6	1.0	13.7
ACE+CCB	1	.6	1.0	14.7
ACE+BB	3	1.8	2.9	17.6
ACE + Aldosteron inh	1	.6	1.0	18.6
ARB+CCB	5	2.9	4.9	23.5
ARB+BB	16	9.4	15.7	39.2
ARB+Diuretik	4	2.3	3.9	43.1
ARB+Aldosteron inh	6	3.5	5.9	49.0
CCB+BB	4	2.3	3.9	52.9
CCB+Aldosteron inh	2	1.2	2.0	54.9
Valid BB+Diuretik	1	.6	1.0	55.9
BB + aldosteron inh	1	.6	1.0	56.9
Diuretik+aldosteron inh	1	.6	1.0	57.8
ACE+CCB+BB	1	.6	1.0	58.8
ACE+BB+Aldosteron inh	3	1.8	2.9	61.8
ARB+CCB+BB	12	7.0	11.8	73.5
ARB+CCB+Diuretik	2	1.2	2.0	75.5
ARB+CCB+Aldosteron inh	2	1.2	2.0	77.5
ARB+BB+Diuretik	3	1.8	2.9	80.4
ARB+BB+Aldosteron inh	7	4.1	6.9	87.3
ARB+Diuretik+Aldosteron inh	7	4.1	6.9	94.1
CCB+BB+Diretik	1	.6	1.0	95.1

	CCB+BB+Aldosteron inh	3	1.8	2.9	98.0
	ARB+BB+Diuretik+Aldosteron inh	2	1.2	2.0	100.0
	Total	102	59.6	100.0	
Missing	System	69	40.4		
Total		171	100.0		

terapi IHD

		Frekuensi	Percent	Valid Percent	Cumulative Percent
Valid	ACE	1	.6	1.5	1.5
	ARB	9	5.3	13.2	14.7
	CCB	1	.6	1.5	16.2
	BB	7	4.1	10.3	26.5
	ACE+CCB	2	1.2	2.9	29.4
	ACE+BB	4	2.3	5.9	35.3
	ARB+CCB	5	2.9	7.4	42.6
	ARB+BB	16	9.4	23.5	66.2
	ARB+Aldosteron inh	1	.6	1.5	67.6
	CCB+BB	3	1.8	4.4	72.1
	BB+Aldosteron inh	1	.6	1.5	73.5
	ACE+CCB+BB	1	.6	1.5	75.0
	ARB+CCB+BB	11	6.4	16.2	91.2
	ARB+CCB+Diuretik	2	1.2	2.9	94.1
	ARB+BB+Diuretik	1	.6	1.5	95.6
	ARB+BB+Aldosteron inh	2	1.2	2.9	98.5
	ARB+Diuretik+Aldosteron inh	1	.6	1.5	100.0
	Total	68	39.8	100.0	
	Missing	System	103	60.2	
Total		171	100.0		

Lampiran 4. Biodata Mahasiswa

Nama : Ainurrizqi Intan Puspitasari
NIM : 22010111120029
Tempat/tanggal lahir : Tanjungpinang, 27 Juli 1993
Jenis kelamin : Perempuan
Alamat : Jalan Kotapiring Gang Putri Riau V Lorong X, RT 3 RW 7,
Kelurahan Melayu Kotapiring, Tanjungpinang Timur,
Tanjungpinang, Kepulauan Riau
Nomor Telepon : (0771) 443517
Nomor HP : 085264442377
e-mail : ainurrizqiintan@gmail.com

Riwayat Pendidikan Formal

1. SD : SD Negeri 014 Bukit Bestari Lulus tahun:2005
2. SMP : SMP Negeri 1 Tanjungpinang Lulus tahun:2008
3. SMA : SMA Negeri 1 Tanjungpinang Lulus tahun: 2011
4. FK UNDIP : Masuk tahun 2011

Keanggotaan Organisasi

1. Asisten Mahasiswa Bagian Fisika Medik tahun 2012
2. HIMA KU FK Undip Tahun 2012 s/d 2015
3. ROHISKU FK UNDIP Tahun 2012 s/d 2013
4. KSM Tahun 2012 s/d 2013
5. AMSA Tahun 2011s/d 2012
6. Mer C Tahun 2014 s/d sekarang
7. AMT Tahun 2013 s/d sekarang

Pengalaman mengikuti lomba karya ilmiah

1. Ainurrizqi Intan Puspitasari, I Gusti Agung Ratih Krisnandari Putri, Khilyatul Mufida, *Restorative Yoga for Breast Cancer Survivors : Physical and Psychological Benefits*, INAMSC 2013, Semifinal (*literature review*)
2. Ainurrizqi Intan Puspitasari, I Gusti Agung Ratih Krisnandari Putri, Potensi Jahe (*Zingiber officinale*) sebagai antiinflamasi dan neuroprotektif dalam terapi preventif penyakit Alzheimer. Temilnas 2012 UMY, Final (Poster Ilmiah)